Information for Tirzepatide

Tirzepatide was developed to fight type 2 diabetes, but has additionally been shown to protect the cardiovascular system and act as a potent weight loss agent. Tirzepatide is a synthetic derivative of gastric inhibitory polypeptide (GIP) that has simultaneous glucagon-like peptide-1 (GLP-1) functionality as well.

Tirzepatide 30mg

Research Certificates of Analysis

Tirzepatide
17.74mg
Task #42383
Batch #04072024
04/12/2024
Tirzepatide
30.25mg
Task #42388
Batch #04162024
04/23/2024
Tirzepatide
34.15mg
Task #48136
Batch #08022024
08/02/2024
Tirzepatide
30.02mg
Task #48957
Batch #09122024
09/12/2024
Tirzepatide
12.06mg
Task #46312
Batch FTIR-0001
08/01/2024
Tirzepatide
33.78mg
Task #52583
Batch #1002
11/11/2024

GMP Certificates of Analysis

Tirzepatide
15.2mg
Batch #PKTZ15924
09/10/2024
Tirzepatide
30.1mg
Batch #PKTZ30924
09/10/2024
Tirzepatide Chem Structure

Tirzepatide Peptide Structure

Source: PubChem

Amino Acid Sequence: YE-Aib-GTFTSDYSI-Aib-LDKIAQ (C20 fatty acid) AFVQWLIAGGPSSGAPPPS
Note: Aib is a non-coded (non-proteinogenic) amino acid – H2H-C(CH3)2-COOH
Molecular Formula: C225H348N48O68
Molecular Weight: 4813.527 g/mol
PubChem CID: 156588324
CAS Number: 2023788-19-2
Synonyms: P1206, LY3298176

What Is Tirzepatide?

  • Regulates blood glucose levels1

  • Encourages weight loss in patients with type 2 diabetes1

  • Enhances insulin release and sensitivity2

  • Improves function of beta cells2

  • Decreases level of LDL cholesterol3

  1. Farzam, K., & Patel, P. (2024, February 20). Tirzepatide. StatPearls - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK585056/#:~:text=Tirzepatide%20is%20a%20dual%20agonist,1%20medications%20such%20as%20semaglutide
  2. Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2020). Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in Type 2 diabetes. ˜the œJournal of Clinical Endocrinology and Metabolism/Journal of Clinical Endocrinology & Metabolism, 106(2), 388–396. https://doi.org/10.1210/clinem/dgaa863
  3. Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020). The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity & Metabolism/Diabetes, Obesity and Metabolism, 22(12), 2451–2459. https://doi.org/10.1111/dom.14174

Product Usage

This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic.